1995
DOI: 10.1254/jjp.67.79
|View full text |Cite
|
Sign up to set email alerts
|

The Essential Amino Acid Domains in Salivary Peptide P-C That Potentiate Glucose-Induced Insulin Release and Inhibit Arginine-Induced Glucagon Release from Perfused Rat Pancreas

Abstract: ABSTRACT-The amino acid domains in salivary peptide P-C (1-44 peptide fragments, P-C) that are essential to potentiate insulin release and inhibit glucagon release were investigated using isolated perfused rat pancreas. P-C significantly potentiated not only glucose (8.3 mM)-induced insulin release, but also arginine (10 mM)-induced insulin release. The essential domain responsible for potentiation of insulin release was the P-C-(23-29) fragment, 23KPQGPPP29, while that inhibiting glucagon release was the P-C-… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2000
2000
2018
2018

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 15 publications
0
2
0
Order By: Relevance
“…Human saliva contains a proline-rich salivary peptide P-C, which potentiates glucose-induced insulin release and inhibits arginine-induced glucagon release in the rat pancreas (Kimura et al 1995, Kimura et al 1998. Insulin-like immunoreactivity has been extensively reported in rodent salivary glands, human parotid (Murakami et al 1982) and submandibular salivary glands (Shubnikova et al 1984), and in human saliva (Fekete et al 1993).…”
Section: Introductionmentioning
confidence: 99%
“…Human saliva contains a proline-rich salivary peptide P-C, which potentiates glucose-induced insulin release and inhibits arginine-induced glucagon release in the rat pancreas (Kimura et al 1995, Kimura et al 1998. Insulin-like immunoreactivity has been extensively reported in rodent salivary glands, human parotid (Murakami et al 1982) and submandibular salivary glands (Shubnikova et al 1984), and in human saliva (Fekete et al 1993).…”
Section: Introductionmentioning
confidence: 99%
“…Salivatin may also be absorbed through the mucosa of those digestive organs. Since a fragment of salivatin, QGPP, also facilitates insulin release–in the way same as the full‐length of salivatin[24]–partially digested, truncated salivatin may be readily absorbed through the digestive tracts and exert an endocrine effect. Xerostomia is a common symptom described in textbooks on diabetes although it is apparently not common in patients with mild type 2 diabetes.…”
Section: Discussionmentioning
confidence: 99%